scholarly journals Improving the potency of DNA vaccine encoding HIV-1 Nef antigen using two endogenous adjuvants in mouse model

2017 ◽  
Vol 118 (09) ◽  
pp. 564-569 ◽  
Author(s):  
B. S. Jafarzade ◽  
S. M. Sadat ◽  
R. Yaghobi ◽  
A. Bolhassani
Keyword(s):  
Mouse Model ◽  
Dna Vaccine ◽  
Hiv 1

Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen

Vaccine ◽  
2004 ◽  
Vol 22 (13-14) ◽  
pp. 1692-1699 ◽  
Author(s):  
Larisa I Karpenko ◽  
Nadezhda A Nekrasova ◽  
Alexander A Ilyichev ◽  
Leonid R Lebedev ◽  
George M Ignatyev ◽  
...  
Keyword(s):  
Comparative Analysis ◽  
Mouse Model ◽  
Dna Vaccine ◽  
Hiv 1

Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model

Vaccine ◽  
2004 ◽  
Vol 22 (13-14) ◽  
pp. 1764-1772 ◽  
Author(s):  
Fangjun Liu ◽  
Innocent Mboudjeka ◽  
Siyuan Shen ◽  
Te-Hui W. Chou ◽  
Shixia Wang ◽  
...  
Keyword(s):  
Mouse Model ◽  
Dna Vaccine ◽  
Codon Optimization ◽  
Synergistic Enhancement ◽  
Gp120 Glycoprotein ◽  
Hiv 1

PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemia

10.1038/nm949 ◽  
2003 ◽  
Vol 9 (11) ◽  
pp. 1413-1417 ◽  
Author(s):  
Rose Ann Padua ◽  
Jerome Larghero ◽  
Marie Robin ◽  
Carol le Pogam ◽  
Marie-Helene Schlageter ◽  
...  
Keyword(s):  
Mouse Model ◽  
Dna Vaccine ◽  
Protective Immunity

Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes

AIDS ◽  
2000 ◽  
Vol 14 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Velpandi Ayyavoo ◽  
Sagar Kudchodkar ◽  
Mathura P. Ramanathan ◽  
Phong Le ◽  
Karuppiah Muthumani ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Dna Vaccine ◽  
Accessory Genes ◽  
Immunodeficiency Virus ◽  
Hiv 1

scholarly journals Enhanced Prophylactic and Therapeutic Effects of Polylysine-Modified Ara h 2 DNA Vaccine in a Mouse Model of Peanut Allergy

2016 ◽  
Vol 171 (3-4) ◽  
pp. 241-250 ◽  
Author(s):  
Zhenlai Zhu ◽  
Jinlei Yu ◽  
Yuan Niu ◽  
Shuhong Sun ◽  
Yufeng Liu ◽  
...  
Keyword(s):  
Mouse Model ◽  
Dna Vaccine ◽  
Peanut Allergy ◽  
Therapeutic Effects ◽  
Ara H 2

scholarly journals Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1

2005 ◽  
Vol 86 (2) ◽  
pp. 349-354 ◽  
Author(s):  
Eva K. L. Nordström ◽  
Mattias N. E. Forsell ◽  
Christina Barnfield ◽  
Eivor Bonin ◽  
Tomas Hanke ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
T Cell ◽  
Dna Vaccine ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Semliki Forest Virus ◽  
Cell Responses ◽  
Immunodeficiency Virus ◽  
Hiv 1

With the human immunodeficiency virus type 1 (HIV-1) epidemic expanding at increasing speed, development of a safe and effective vaccine remains a high priority. One of the most central vaccine platforms considered is plasmid DNA. However, high doses of DNA and several immunizations are typically needed to achieve detectable T-cell responses. In this study, a Semliki Forest virus replicon DNA vaccine designed for human clinical trials, DREP.HIVA, encoding an antigen that is currently being used in human trials in the context of a conventional DNA plasmid, pTHr.HIVA, was generated. It was shown that a single immunization of DREP.HIVA stimulated HIV-1-specific T-cell responses in mice, suggesting that the poor immunogenicity of conventional DNA vaccines may be enhanced by using viral replicon-based plasmid systems. The results presented here support the evaluation of Semliki Forest virus replicon DNA vaccines in non-human primates and in clinical studies.

Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine

Vaccine ◽  
2002 ◽  
Vol 20 (23-24) ◽  
pp. 2857-2865 ◽  
Author(s):  
Y KOJIMA
Keyword(s):  
Dna Vaccine ◽  
Adjuvant Effect ◽  
Cpg Motifs ◽  
Hiv 1

Development and Evaluation of a DNA Vaccine Based on Helicobacter pylori urease B: Failure to Prevent Experimental Infection in the Mouse Model

Helicobacter ◽  
2006 ◽  
Vol 11 (6) ◽  
pp. 517-522 ◽  
Author(s):  
Livania Zavala-Spinetti ◽  
Mary B. Breslin ◽  
Hernán Correa ◽  
Rodolfo E. Bégué
Keyword(s):  
Helicobacter Pylori ◽  
Mouse Model ◽  
Dna Vaccine ◽  
Experimental Infection

scholarly journals A Novel Tuberculosis DNA Vaccine in an HIV-1 p24 Protein Backbone Confers Protection against Mycobacterium tuberculosis and Simultaneously Elicits Robust Humoral and Cellular Responses to HIV-1

2012 ◽  
Vol 19 (5) ◽  
pp. 723-730 ◽  
Author(s):  
Xiaoman Li ◽  
Wei Xu ◽  
Sidong Xiong
Keyword(s):  
Mycobacterium Tuberculosis ◽  
T Cell ◽  
Dna Vaccine ◽  
Cellular Response ◽  
Mycobacterial Infection ◽  
T Cell Epitopes ◽  
Content Type ◽  
P24 Protein ◽  
Elevated Frequency ◽  
Hiv 1

ABSTRACTTuberculosis (TB) caused byMycobacterium tuberculosisremains a major infectious disease worldwide. Moreover, latentM. tuberculosisinfection is more likely to progress to active TB and eventually leads to death when HIV infection is involved. Thus, it is urgent to develop a novel TB vaccine with immunogenicity to bothM. tuberculosisand HIV. In this study, four uncharacterized T cell epitopes from MPT64, Ag85A, Ag85B, and TB10.4 antigens ofM. tuberculosiswere predicted, and HIV-1-derived p24, an immunodominant protein that can induce protective responses to HIV-1, was used as an immunogenic backbone.M. tuberculosisepitopes were incorporated separately into the gene backbone of p24, forming a pP24-Mtb DNA vaccine. We demonstrated that pP24-Mtb immunization induced a strongM. tuberculosis-specific cellular response as evidenced by T cell proliferation, cytotoxicity, and elevated frequency of gamma interferon (IFN-γ)-secreting T cells. Interestingly, a p24-specific cellular response and high levels of p24-specific IgG were also induced by pP24-Mtb immunization. When the protective effect was assessed after mycobacterial challenge, pP24-Mtb vaccination significantly reduced tissue bacterial loads and profoundly attenuated the mycobacterial infection-related lung inflammation and injury. Our findings demonstrated that the pP24-Mtb tuberculosis vaccine confers effective protection against mycobacterial challenge with simultaneously elicited robust immune responses to HIV-1, which may provide clues for developing novel vaccines to prevent dual infections.

Sign in / Sign up

Export Citation Format

Share Document